MIR1290 (MicroRNA 1290)

miR-223-3p, both alone and in combination with miR-1290 and miR-1246, demonstrated optimal performance in distinguishing HRR from SIRR patients (AUC = 0.68, 95% CI: 0.52-0.84; AUC = 0.69, 95% CI: 0.53-0.84, respectively). These preliminary findings indicate that miR-223-3p, whether used independently or in conjunction with miR-1246 and miR-1290, may serve as promising non-invasive MRD biomarkers in pediatric ALL. Further validation in larger patient cohorts is necessary to corroborate these results.

Circulating miRNAs, including hsa-miR-3619-3p, hsa-miR-1290, and hsa-miR-1185-2-3p, correlated with AFP levels and disease stage, underscoring their value as non-invasive biomarkers. These findings demonstrate that integrated analysis of tissue and serum miRNAs can identify clinically relevant biomarkers and potential therapeutic targets in HCC.

Validation across the total dataset and five GSE datasets (GSE106817, GSE112264, GSE113486, GSE113740, and GSE164174) yielded AUCs of 0.997, 0.999, 1.000, 1.000, 0.996, and 0.994, respectively. The novel miRNA set comprising miR-1290, miR-5100, miR-1343-3p, miR-8073, miR-4706, and miR-4787-3p holds promise as a diagnostic classifier for GC screening.

This investigation identified modular genes and miRNAs linked to CRC liver metastasis, along with metabolism-associated differentially expressed mRNAs. These pivotal mRNAs and miRNAs could be instrumental in elucidating the biological mechanisms underpinning CRC liver metastasis and suggesting candidate biomarkers.

Using the largest known sample size and the most complex mixed cohort, we have successfully devised efficient screening models for prostate cancer, namely PCa4miR and PCaSS. These models have demonstrated exceptional screening accuracy, underscoring their capacity for the early detection of prostate cancer.

A 2024 review in the Journal of Pharmaceutical Investigatio 3 highlights the biological advantages of EVs, particularly their ability to protect and deliver miRNAs with enhanced stability and targeting efficiency. Similarly, the Springer volume Extracellular Vesicle: Biology and Translational Application 4 details the mechanisms of EV biogenesis and cargo selection, reinforcing the notion that EVs offer a more reliable platform for miRNA-based diagnostics.

Enz/AR/CDR1/circCDR1-AS signaling might then increase BMP4 expression by altering miR-1290 expression, which involves direct binding to the 3' UTR of BMP4 mRNA. Preclinical studies using a CWR22Rv1 xenograft mouse model and integrative analysis of GEO cohort data further demonstrated that targeting this newly identified Enz/AR/CDR1/circCDR1-AS/miR-1290/BMP4 signaling pathway with miR-1290, circCDR1-AS-shRNA, or BMP4-shRNA may help develop novel therapies to combat Enz resistance at the later stage of CRPC.

These findings suggest that exosomes not only reflect the pathophysiology of ALL but may also play a crucial role in its development and progression. Furthermore, exosomes and their non-coding RNA content emerge as potential biomarkers for ALL diagnosis and prognosis, opening avenues for future research to explore their functional role and therapeutic potential.

Combining the four miRNAs with carcinoembryonic antigen improved diagnostic accuracy, with an area under the curve of 0.82 (95% confidence interval: 0.74-0.89). Exosomal miRNAs derived from colorectal cancer organoids can serve as diagnostic biomarkers for colorectal cancer.

MiR-1290 emerges as a promising biomarker for predicting seizure susceptibility and overall survival in GBM patients. A specific evaluation of miR-1290 may lead to targeted diagnostic and therapeutic interventions, potentially providing novel strategies for enhancing patient outcomes.

A prediction model combining serum miRNA biomarkers and nodule size showed high predictive power for lung cancer. Integration of the prediction model into current lung cancer screening protocols may improve patient outcomes.

Basic experiments showed that miR-300, miR-361-5p, miR-1246, and miR-1290 enhanced the stemness characteristics of NPC cells, promoting proliferation, invasion, and migration. These findings suggest that these four stemness-related miRNAs could serve as therapeutic targets, potentially improving therapeutic responses by targeting stemness-related genes.